NEXAVAR for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 16 adverse event reports in the FDA FAERS database where NEXAVAR was used for Renal cell carcinoma.
Most Reported Side Effects for NEXAVAR
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 46 | 12.6% | 14 | 18 |
| Hepatocellular carcinoma | 42 | 11.5% | 33 | 12 |
| Palmar-plantar erythrodysaesthesia syndrome | 36 | 9.9% | 16 | 11 |
| Hepatic cancer | 27 | 7.4% | 9 | 8 |
| Decreased appetite | 24 | 6.6% | 9 | 12 |
| Hypertension | 22 | 6.0% | 8 | 8 |
| Fatigue | 20 | 5.5% | 5 | 7 |
| Renal cancer | 20 | 5.5% | 1 | 0 |
| Rash | 19 | 5.2% | 6 | 6 |
| Abdominal pain | 18 | 4.9% | 4 | 10 |
| Nausea | 18 | 4.9% | 5 | 12 |
| Pain in extremity | 18 | 4.9% | 3 | 6 |
| Ascites | 17 | 4.7% | 10 | 12 |
| Death | 17 | 4.7% | 16 | 4 |
| Hepatic encephalopathy | 17 | 4.7% | 9 | 13 |
Other Indications for NEXAVAR
Hepatocellular carcinoma (141)
Hepatic cancer (103)
Renal cancer (29)
Thyroid cancer (10)
Metastases to lung (6)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)